PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

AI in Drug Discovery
Auto Draft
Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

OGT unveils NGS automation for SureSeq workflows, streamlining NGS library preparation

Delivering reduced hands-on time, more consistent results and higher sample throughput

OGT, a leading global provider of genomic research and diagnostic solutions today unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq™ NGS portfolio, compatible with the Hamilton NGS STAR Line. The latest advancement in OGT’s ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets.

Rising sample volumes are putting clinical research labs under pressure. Maintaining consistent throughput while managing labour-intensive library preparation is a growing bottleneck, one that OGT has addressed head-on. Developed in close collaboration with laboratory partners and workflow specialists, automation-enabled SureSeq workflows remove manual intervention at the most time-consuming stages of NGS library preparation, supporting high-throughput processing across multiple sample types.

The result: A faster, more consistent process for NGS results without additional resource burden.

“NGS automation is essential for high-volume labs to get the most out of their NGS analysis,” said Adrian Smith, CEO of OGT. “By removing labour-intensive manual steps, labs can dramatically increase capacity, improve reproducibility and consistency allowing them to focus their teams where it matters most.”

Combined with OGT’s wide range of haematological malignancy-focused SureSeq NGS panels, including the recently launched SureSeq Myeloid MRD Plus NGS Panel, SureSeq solutions give clinical research labs the throughput and confidence to extract clear, comprehensive genomics insights at scale.

For more information about SureSeq NGS workflows and OGT’s genomics solutions, please visit: www.ogt.com

For further information, please contact:

Oxford Gene Technology, Unit 5, Oxford Technology Park, 4A Technology Drive, Kidlington, Oxfordshire, OX5 1GN, United Kingdom

T: +441865 856800

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC